Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05589753 · ClinicalTrials.gov registry record · Phase 1
Sleep Disordered Breathing With Opioid Use
A Phase 1 study of Opioid Use and Sleep Apnea, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05589753 is a Phase 1 study of Opioid Use and Sleep Apnea that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 150 participants, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05589753, a Phase 1 study of Opioid Use and Sleep Apnea, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
There is an increased risk for sleep disordered breathing (SDB), sleep-related hypoventilation and irregular breathing in individuals on chronic prescription opioid medications. Almost 30% of a veteran sleep clinic population had opioid-associated central sleep apnea (CSA). The proposal aims to identity whether oxygen and acetazolamide can be effective in reducing unstable breathing and eliminating sleep apnea in chronic opioid use via different mechanisms. We will study additional clinical parameters like quality of life, sleep and pain in patients with and without opioid use. This proposal will enhance the investigators' understanding of the pathways that contribute to the development of sleep apnea with opioid use. The investigators expect that the results obtained from this study will positively impact the health of Veterans by identifying new treatment modalities for sleep apnea.
Conditions Studied
Interventions
- DRUG Acetazolamide
- OTHER Hyperoxia
Study Locations (1)
Michigan
- John D. Dingell VA Medical Center, Detroit, MI - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05589753
The ClinicalTrials.gov registry entry for NCT05589753 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Opioid Use appearing as the primary indexed condition, and to 2 interventions - of which Acetazolamide is the first listed.
NCT05589753 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05589753 about?
NCT05589753 is a clinical study titled "Sleep Disordered Breathing With Opioid Use". There is an increased risk for sleep disordered breathing (SDB), sleep-related hypoventilation and irregular breathing in individuals on chronic prescription opioid medications. Almost 30% of a veteran sleep clinic population had opioid-associated central sleep apnea (CSA). The proposal aims to iden...
What is the current status of trial NCT05589753?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2019-05-02. Estimated completion is 2027-03-31.
What conditions does trial NCT05589753 study?
This clinical trial studies the following conditions: Opioid Use, Sleep Apnea, Sleep Disordered Breathing.
What interventions are being tested in trial NCT05589753?
The interventions under investigation include: Acetazolamide (DRUG), Hyperoxia (OTHER).
Who is sponsoring clinical trial NCT05589753?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05589753 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty
ACTIVE NOT RECRUITING · Phase 1
-
The Behavioral Effects of Opioids and Alcohol
COMPLETED · Phase 1
-
Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression
RECRUITING · Phase 3
-
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
RECRUITING · Phase 4
-
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
RECRUITING · Phase 3
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.